Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2015 May 4;10(5):e0128052. doi: 10.1371/journal.pone.0128052

Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy

Tal I Arnon, Gal Markel, Ahuva Bar-Ilan, Jacob Hanna, Eyal Fima, Fabrice Benchetrit, Ruth Galili, Adelheid Cerwenka, Daniel Benharroch, Netta Sion-Vardy, Angel Porgador, Ofer Mandelboim
PMCID: PMC4418968  PMID: 25938552

There are errors in Fig 4, “Summary of fusion protein treatment”. Fig 4a contains the wrong set of images for PBS (control) injected mice. Please see the corrected Fig 4 here.

Fig 4. Summary of fusion protein treatment.

Fig 4

(a) Visualization of tumor progression and distribution in vivo. The figure shows an image visualization of one representative animal of each treatment. The scale on the right of each figure describes the color map of the photon count. The integrated light emission (‘I’) is indicated in the left of each photo. (b) Summary of treatment effect. Table describes the overall effect of treatments, as shown in details in Fig 3.

Reference


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES